<DOC>
	<DOCNO>NCT00971113</DOCNO>
	<brief_summary>The human intestinal microflora characterize complex dynamic microbial ecosystem crucial contribution nutrition welfare . Health-promoting genus Bifidobacterium spp . Lactobacillus spp . play key role digestion nutrient , production short chain fatty acid vitamin , inhibition harmful bacteria , immunostimulation , reduction blood cholesterol ammonia level restoration normal flora antibiotic therapy . Proteolytic specie toxin-producing clostridia toxigenic E. coli consider potential pathogen detrimental effect human host . Recently , part novel food research directing towards concept prebiotics e.g . food ingredient hydrolyze human gastrointestinal tract beneficially affect host selectively stimulating growth and/or activity one limited number bacteria colon improve host health . Fructo-oligosaccharides inulin , consider extensively study well-established prebiotics . In vitro vivo data suggest bifidogenic effect inulin oligofructose , attribute selective fermentation Bifidobacterium specie . Due document prebiotic property , inulin FOS increasingly apply novel food product development fortification commonly ingested foodstuff . The aim study evaluate vivo prebiotic effect functional food contain short-chain fructo-oligosaccharides ( sc-FOS ) Sideritis euboea extract faecal microflora composition healthy human volunteer .</brief_summary>
	<brief_title>Prebiotic Effect Jelly Containing Short Chain Fructo-Oligosaccharides Sideritis Euboea Extract</brief_title>
	<detailed_description>In randomize , double-blinded , placebo-controlled clinical study aim evaluate vivo prebiotic effect functional food contain short-chain fructo-oligosaccharides ( sc-FOS ) Sideritis euboea extract human faecal microflora . Sixty-four healthy volunteer ( 26 men 38 woman ) ( age range:22-51 ) assign consume daily jelly contain 5 g sc-FOS 0.3 g S.euboea extract placebo 30 d. Stool sample collect prior study day 15 30 intervention 2 week . Enumeration faecal bacteria perform plate count technique . Gastrointestinal side effect record treatment period .</detailed_description>
	<criteria>Healthy adult subject History gastrointestinal disease Chronic diseases ( i.e. , diabetes , cardiovascular disease , hyperlipidemia , autoimmune disorder ) History epileptic seizure Extreme dietary behaviour Consumption antibiotic medication 2 month prior investigation period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>